Literature DB >> 2281427

Inhaled micronised gentamicin powder: a new delivery system.

J M Goldman1, S M Bayston, S O'Connor, R E Meigh.   

Abstract

Forty patients undergoing routine bronchoscopy were randomised to receive inhaled micronised gentamicin powder (180 mg) or nebulised gentamicin solution (160 mg) one hour before the procedure. Similar levels of gentamicin were detected in bronchoalveolar lavage fluid in the two groups (micronised powder (n = 20) 9.3 (SD 9.3) mg/l, nebulised solution (n = 20) 8.0 (7.8) mg/l). The micronised gentamicin powder preparation caused cough in half the patients but this did not stop their receiving a full dose. Dry powder gentamicin may be a convenient formulation for long term inhaled treatment if the problem of cough can be overcome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2281427      PMCID: PMC462842          DOI: 10.1136/thx.45.12.939

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  3 in total

1.  Inhaled antibiotics in cystic fibrosis.

Authors:  M A Wall; A B Terry; J Eisenberg; M McNamara; R Cohen
Journal:  Lancet       Date:  1983-06-11       Impact factor: 79.321

2.  Partial preservation of pancreatic beta-cell function in children with diabetes.

Authors:  R B Elliott; J R Crossley; C C Berryman; A G James
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

3.  Evaluation of jet nebulisers for use with gentamicin solution.

Authors:  S P Newman; P G Pellow; M M Clay; S W Clarke
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

  3 in total
  6 in total

1.  Microparticles for inhalational delivery of antipseudomonal antibiotics.

Authors:  Michael D Tsifansky; Yoon Yeo; Oleg V Evgenov; Evangelia Bellas; John Benjamin; Daniel S Kohane
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

Review 2.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 3.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Authors:  David E Geller; Jeffry Weers; Silvia Heuerding
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-11       Impact factor: 2.849

4.  An alternative aerosol delivery system for amiloride.

Authors:  M L Everard; S G Devadason; V B Sunderland; P N Le Souef
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

5.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

Review 6.  Pharmaceutical aerosols for the treatment and prevention of tuberculosis.

Authors:  Shumaila N M Hanif; Lucila Garcia-Contreras
Journal:  Front Cell Infect Microbiol       Date:  2012-09-07       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.